REG - Frontier Dev PLC - EBT Share Purchase

Frontier DevelopmentsAnnouncement

10/09/2018 07:05

RNS Number : 1980A
Frontier Developments PLC
10 September 2018
 


10 September 2018
 
Frontier Developments plc
(the "Company")
 
EBT Share Purchase
 
The Company was notified on 7 September 2018, by the trustee of the Frontier Developments plc Employee Benefit Trust (the "EBT"), that the EBT had purchased 237,346 ordinary shares in the Company at an average price of £10.262204 per ordinary share on 7 September 2018. These ordinary shares are to be held in the EBT and are intended to be used to satisfy the exercise of share options by employees. The EBT is a discretionary trust for the benefit of the Company's employees, including the Directors of the Company.
 
Following this transaction, a total of 341,991 Ordinary Shares are held by the Company's employee benefit trust, representing 0.883 per cent of the Company's total voting rights.
 
Enquiries:




Frontier Developments


+44 (0)1223 394 300




David Braben, CEO
Alex Bevis, CFO
 


 




 


 




Liberum - Nomad and Joint Broker


+44 (0)203 100 2000




Neil Patel /Cameron Duncan/William Hall


 




 


 




 
Finncap


+44 (0) 207 220 0500




Matt Goode/Giles Rolls


 




 


 




 
Tulchan Communications


+44 (0) 207 353 4200




James Macey White/Matt Low


 




 
 
About Frontier Developments plc 
Frontier Developments plc, listed on the AIM stock market (AIM: FDEV), is a leading independent creator of self-published video game franchises founded in 1994 by David Braben, co-author of the seminal Elite game. Based in Cambridge, Frontier uses its proprietary 'COBRA' game development technology to create innovative games, currently focusing on video game consoles and personal computers.
 
Frontier's LEI number: 213800B9LGPWUAZ9GX18.
 
www.frontier.co.uk                 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHLLFVIALIAIIT